{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T17:24:13Z","timestamp":1782494653454,"version":"3.54.5"},"reference-count":25,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2011,12,6]],"date-time":"2011-12-06T00:00:00Z","timestamp":1323129600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2012,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>High doses of gabapentin were associated with pancreatic acinar cell tumors in male Wistar rats, but there is little published epidemiological data regarding gabapentin and carcinogenicity. We explored the association between gabapentin and cancer in a US medical care program and followed up nominally significant associations in a UK primary care database.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In the US Kaiser Permanente Northern California (KPNC) health system, we performed nested case\u2013control analyses of gabapentin and 55 cancer sites and all cancers combined using conditional logistic regression. Up to 10 controls were matched to each case on year of birth, sex, and year of cohort entry. No other covariates were included in models. Only dispensings for gabapentin 2\u2009years or more before index date were considered. Nominally significant associations with an OR\u2009&gt;\u20091.00 and <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05 for three or more dispensings versus no dispensings were followed up by similar nested case\u2013control analyses in the UK General Practice Research Database (GPRD), adjusting for potential indications for gabapentin and risk factors for the specific cancers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The following analyses had OR\u2009&gt;\u20091.00 and <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05 for three or more dispensings of gabapentin versus no dispensing (2\u2010year lag) in KPNC and were also examined in the GPRD: all cancers, breast, lung and bronchus, urinary bladder, kidney\/renal pelvis, stomach, anus\/anal canal\/anorectum, penis, and other nervous system. These cancers were not statistically significantly associated with gabapentin in the GPRD case\u2013control studies (2\u2010year lag). The GPRD and KPNC studies did not identify a statistically significant increased risk of pancreatic cancer with more than two prescriptions of gabapentin in the 2\u2010year lagged analyses.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The epidemiological data in a US cohort with up to 12\u2009years of follow\u2010up and a UK cohort with up to 15\u2009years of follow\u2010up do not support a carcinogenic effect of gabapentin use. However, the confidence intervals for some analyses were wide, and an important effect cannot be confidently excluded. Copyright \u00a9 2011 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.2266","type":"journal-article","created":{"date-parts":[[2011,12,6]],"date-time":"2011-12-06T08:04:10Z","timestamp":1323158650000},"page":"214-225","source":"Crossref","is-referenced-by-count":12,"title":["Risk of cancer in patients exposed to gabapentin in two electronic medical record systems"],"prefix":"10.1002","volume":"21","author":[{"given":"Michael C.","family":"Irizarry","sequence":"first","affiliation":[{"name":"WW Epidemiology GlaxoSmithKline  Research Triangle Park NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Webb","sequence":"additional","affiliation":[{"name":"WW Epidemiology GlaxoSmithKline  Stockley Park UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada","family":"Boudiaf","sequence":"additional","affiliation":[{"name":"WW Epidemiology GlaxoSmithKline  Stockley Park UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Logie","sequence":"additional","affiliation":[{"name":"WW Epidemiology GlaxoSmithKline  Stockley Park UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurel A.","family":"Habel","sequence":"additional","affiliation":[{"name":"Division of Research Kaiser Permanente Medical Care Program  Oakland CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Udaltsova","sequence":"additional","affiliation":[{"name":"Division of Research Kaiser Permanente Medical Care Program  Oakland CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary D.","family":"Friedman","sequence":"additional","affiliation":[{"name":"Division of Research Kaiser Permanente Medical Care Program  Oakland CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,12,6]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2003.9.6.559"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4637.2010.00840.x"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/0300-483X(94)02966-X"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10552-009-9375-2"},{"key":"e_1_2_7_6_1","volume-title":"SEER Program Coding and Staging Manual","author":"National Cancer Institute","year":"2007"},{"key":"e_1_2_7_7_1","first-page":"489","volume-title":"Cancer Epidemiology and Prevention","author":"Habel LA","year":"1996"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/91.6.445"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2009.177"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.10.040"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602619"},{"key":"e_1_2_7_12_1","first-page":"33","article-title":"Epidemiologic characteristics and risk factors for renal cell cancer","volume":"1","author":"Lipworth L","year":"2009","journal-title":"Clin Epidemiol"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6600267"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001648-200111000-00018"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-04-0467"},{"key":"e_1_2_7_16_1","unstructured":"Risk of cancer in patients exposed to gabapentin in the GPRD. GSK Clinical Trial Register.2011.http:\/\/www.gsk\u2010clinicalstudyregister.com\/"},{"key":"e_1_2_7_17_1","first-page":"232","volume-title":"Statistical Methods in Cancer Research Volume II: The Design and Analysis of Cohort Studies","author":"Breslow NE","year":"1987"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/00045391-200205000-00005"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1360"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(81)90038-2"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(80)90363-0"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001648-199607000-00016"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)15841-8"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2009.03537.x"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)80084-0"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.3.349"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.2266","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.2266","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.2266","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T23:11:55Z","timestamp":1695510715000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.2266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,6]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["10.1002\/pds.2266"],"URL":"https:\/\/doi.org\/10.1002\/pds.2266","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,6]]}}}